Curriculum · Metabolic and Endocrine and Diabetes Mellitus
Metformin and iodinated contrast
What it is
Metformin is the first line treatment for type 2 diabetes. It is not nephrotoxic in itself, but it is secreted by the kidney; so where the kidney cannot clear it, it accumulates in the blood causing lactic acidosis. That one line stands behind every rule below.
How it is treated
Hold metformin for 24 hours before procedures using contrast dye.
The renal rule beside it is written by eGFR. Where there is nephropathy with eGFR of 30 or less, metformin has to be stopped. At GFR 30 to 40, modify the dose, or, if the patient is not on metformin, do not start giving it.
Apart from the kidney, it should be taken after food to minimize GI upset.
What can go wrong
The listed contraindications are a serum creatinine of 1.5 mg/dL or greater in men and 1.4 mg/dL or greater in women; a creatinine clearance less than 30 mL/minute; severe hepatic, pulmonary, or cardiac disease; holding for 24 hours before procedures using contrast dye; excessive alcohol intake; and hypoxemia, dehydration, or sepsis.
What the drug does to the patient is split in two. Common: nausea, vomiting, diarrhea, gas, upset stomach and metallic taste, especially early, and weight loss. Uncommon: macrocytic anemia caused by vitamin B12 deficiency, and lactic acidosis. The contrast itself carries two harms. It is one cause of acute tubular necrosis: ATN divides by etiology into ischemic, from all types of shock and drug-induced, and toxic, which is pigment induced from rhabdomyolysis or hemolysis, and contrast-induced. It runs in three phases, initiation, maintenance and recovery. Its management is supportive: minimize nephrotoxic exposures such as drugs and dyes, optimize hydration and volume status, correct electrolyte imbalances, screen for any indication for hemodialysis, and monitor UO and the biochemical indices; and the recovery phase means a degree of polyuria with increased losses of electrolytes, because the tubules are still leaky as they heal. The other harm is the reaction. Radiocontrast media is a non-immunologic mast cell activator, so what it causes is an anaphylactoid, non-IgE-mediated degranulation rather than an IgE-mediated one.